Updated time: 2021-09-28 15:41:28
14A-1030111
TW I627957、US 10987369 B2、CN Patent pending
The invention relates to the discovery that expression of Pdia4 in β cells was up-regulated in response to metabolic stress. Blood Pdia4 was increased in diabetic animals. Moreover, Pdia4 negatively modulated β-cell function. Conversely, decreasing Pdia4 is protective to β-cells. Pdia4 aggravates diabetes development in mouse models. Strikingly, a combination of β-cell preservation, by Pdia4 inhibition/ablation, and reduction of insulin resistance, by insulin sensitizers, metformin, and metformin/rosiglitazone, could reverse diabetes and reduce diabetic complications in preclinical trials.
In one aspect, the invention relates to use of a therapeutically effective amount of a Pdia4 inhibitor in the manufacture of a medicament for preventing, alleviating and/or treating diabetes and/or diabetes-related complications in a subject in need thereof, wherein the Pdia4 inhibitor inhibits Pdia4 protein activity and/or inhibits Pdia4 protein expression.
- Novel discovery showing the link between diabetes and Pdia4.
- The expression levels of Pdia4 are up-regulated in β cells and blood of diabetic mice.
- Pdia4 is localized in nuclear, cytosolic and membrane compartments.
- Use of Pdia4 as diagnosis marker for diabetes.
- Use of Pdia4 as the target of anti-diabetic therapy.
- Use of targeting Pdia4 alone and in combination with other anti-diabetic drugs to prevent and cure.
Wen-Chin Yang, Lee-Tian Chang, Shou-Hsien Huang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

PDIA4 protein as a target for diagnosis, monitoring and treatment of diabetes